| Bid | 1.79 |
| Market Cap | 146.67M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.43 |
| PE Ratio (ttm) | -4.07 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.86 |
| Volume | 11,935 |
| Avg. Volume (20D) | 497,739 |
| Open | 1.82 |
| Previous Close | 1.82 |
| Day's Range | 1.75 - 1.83 |
| 52-Week Range | 1.29 - 3.51 |
| Beta | undefined |
About IPHA
Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizu...
Analyst Forecast
According to 1 analyst ratings, the average rating for IPHA stock is "Buy." The 12-month stock price forecast is $11.5, which is an increase of 557.14% from the latest price.
1 month ago · businesswire.com
Innate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that abstracts related to lacutamab healt...
2 months ago · businesswire.com
Innate Pharma Reports Third Quarter 2024 Business Update and Financial ResultsMARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced its business update and financial results...
